Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 5 of 9« First...34567...Last »

New FDA Head Discusses First Order of Business

The new U.S. FDA Commissioner Scott Gottlieb hit the ground running with an all-staff meeting at the regulatory agency to lay out his priorities and goals.

Read More »

AstraZeneca Sues Former Exec After GlaxoSmithKline Poaches Him Away to Run Its Largest Business

Four months after Luke Miels was hired away by GlaxoSmithKline, AstraZeneca filed a lawsuit claiming Miels is in violation of his employee contract.

Read More »

NY county sues Purdue, J&J over opioid marketing

A county in New York state has sued Purdue Pharma LP, Johnson & Johnson and other drugmakers, accusing them of engaging in fraudulent marketing that played down the risks of prescription opioid painkillers, leading to a drug epidemic.

Read More »

Keeping it Kompliant with the Kardashians: Influencer Marketing & Pharma

Influencer marketing done right can make a big splash.

Read More »

Mesmerize Marketing Announces Acquisition of Elite Sampling & Media Group’s Network of Doctors’ Office Wallboards

Mesmerize Marketing, an established leader in patient education at the point of care (POC) since 2006, announced that it acquired Elite Sampling & Media Group’s national network of doctors’ office wallboards.

Read More »

Safety Concerns Raised for Ionis’ Inotersen

Ionis Pharmaceuticals said its Phase III study of inotersen to treat patients with familial amyloid polyneuropathy (FAP) met primary and secondary endpoints.

Read More »

Poor pharma digital marketing damages credibility with physicians, Manhattan Research study finds

Physicians say most of what they get from drug companies online is just advertising and they feel few pharmas are doing a good job at providing quality digital content.

Read More »

Fitbit Data Reveals List of Fittest Countries and US Cities

Fitbit, the leader in connected health and fitness wearables, for this first time identified its list of Fittest Countries as well as the Fittest Cities in the United States.

Read More »

How AstraZeneca cancer drug forecasts are set to rise

Sales forecasts for AstraZeneca’s all-important new cancer immunotherapy drug Imfinzi are set to rise after the drugmaker received an unexpectedly early boost for the medicine in lung cancer.

Read More »

Aspen under EU antitrust spotlight over excessive cancer drug prices

EU antitrust regulators will investigate whether Aspen Pharmacare is charging excessive prices for five key cancer drugs in a move which could lead to a hefty fine for Africa’s largest generic drugmaker.

Read More »

Thermo Fisher Scientific acquires Patheon

Thermo Fisher Scientific Inc. snapped up North Carolina-based Patheon N.V. in a deal valued at $7.2 billion.

Read More »

Biotech Loses a Legend: Genzyme Founder and Longtime CEO Dies at 71

Biotech innovator Henri Termeer, the longtime chief executive officer of Genzyme and a pioneer in orphan drug development, passed away at the age of 71 years.

Read More »

Vaccine alliance says 300,000 doses of Merck’s Ebola shot available for emergencies

The GAVI global vaccine alliance said some 300,000 emergency doses of an Ebola vaccine developed by Merck could be available in case of a large-scale outbreak, after the World Health Organization confirmed a fatal case in Congo.

Read More »

Migraine drug meets main late-stage studies goal

Patients with episodic and chronic migraine reported fewer debilitating headaches after using Eli Lilly’s experimental drug compared to those on placebo.

Read More »

Durvalumab reduces risk of death from lung cancer

A trial of AstraZeneca’s key immunotherapy drug durvalumab showed it reduced the risk of death from advanced lung cancer.

Read More »

SoCal’s Capricor to Reduce Workforce and Shift Focus After Discouraging Trial Results

Shares of Capricor Therapeutics plunged nearly 60 percent in premarket trading after the company announced it was laying off an unknown number of employees following the failure of a mid-stage cardiovascular drug trial.

Read More »

Top GlaxoSmithKline Investor Cashes Out, Citing a Weak Pipeline and Lack of Strategic Options

Neil Woodford, of UK’s Woodford Investment Management, unloaded his company’s shares of London-based GlaxoSmithKline. His concerns include a weak pipeline and few strategic options.

Read More »

U.S. candymakers band together to reduce calories

Five major chocolate and candy companies announced a joint commitment to reduce calories in many sweets sold on the U.S. market, a rare example of cooperation in a competitive industry and testament to a rising consumer distaste for sugar.

Read More »

WHO wants transparency, market revamp for fairer drug pricing therape

The world needs greater transparency on the pricing of medicines – and an overhaul of some approaches – in order to increase access to life-saving drugs, global health experts said.

Read More »

Digitas Health Names John Mangano to Lead Strategy and Analytics Practice

John Mangano was named senior VP, Strategy and Analytics, at Digitas Health – the Agency of Now.

Read More »

Page 5 of 9« First...34567...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom